EXEL vs SYRE
Exelixis vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | EXEL | SYRE |
|---|
| AI Score |
67
|
67
|
| Price |
$51.30
|
$102.72
|
| P/E Ratio |
15.60×
|
-52.69×
|
| ROE |
36.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
0.0%
|
| Debt / Equity |
0.09×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
53.3
|
| Beta |
0.422
|
3.026
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus SYRE.
The committee scores are tied.
EXEL and SYRE both score 67/100.
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical